Cyberonics reneged on its "Lifetime Reimbursement Guarantee". Click on the image to learn how you can help...
Showing posts with label repetitive transcranial magnetic. Show all posts
Showing posts with label repetitive transcranial magnetic. Show all posts

Tuesday, April 17, 2012

Brainsway in breakthrough for depression treatment

Brainsway in breakthrough for depression treatment

The company reports that treatment with Deep TMS was found to be effective and safe, with no side effects.

17 April 12 11:54, Globes' correspondent
 
Brainsway Ltd. (TASE:BRIN) today announced good results of its multicenter trial of its Deep TMS (transcranial magnetic stimulation) device for the treatment of severe depression. The treatment was found to be effective and safe, with no side effects.
 The trial included 233 patients at four medical centers in Israel, fourteen in the US, one in Canada, and two in Germany. The patients in the trial had previously failed to respond to therapeutic treatments, or suffered from side effects of those treatments.
After five weeks of treatment, there was a statistically significant difference between the patients treated with Deep TMS and the control group, based on the Hamilton Depression Rating Scale: 30.4% of the patients treated with Deep TMS achieved remission, compared with 14.5% of the control group.
The final results of the trial will be received when the database is closed and full statistical analysis of the results is completed.
Brainsway CEO Uzi Sofer said, "We will make a presentation about the results to investors in a few days. We will submit an application to the US Food and Drug Administration (FDA) for this indication by the end the second quarter of 2012."
Since 2008, the FDA has approved use of Deep TMS up to a depth of 1.5-2 centimeters into the brain tissue, although the device can penetrate up to 6-7 centimeters to the parts of the brain that are the source of depression and addiction.
Brainsway has CE Mark for use of Deep TMS for the treatment of depression, manic-depression, and post traumatic stress syndrome. The company expects to begin marketing the device in Latin America this year. A few months ago, it obtained Israel Ministry of Health approval for use of the device for the treatment of depression, manic-depression, and schizophrenia.
Brainsway's share price rose 38.2% by midday to NIS 27.80, giving a market cap of NIS 320 million.


Wednesday, March 7, 2012

The emerging use of brain stimulation treatments for psychiatric disorders.

Aust N Z J Psychiatry. 2011 Nov;45(11):923-38.

The emerging use of brain stimulation treatments for psychiatric disorders.

Source

Monash Alfred Psychiatry Research Centre, The Alfred and Monash University School of Psychology and Psychiatry, Melbourne, Victoria, Australia. paul.fi tzgerald@monash.edu

Abstract

OBJECTIVE:

The aim of this study was to review the current state of development and application of a wide range of brain stimulation approaches in the treatment of psychiatric disorders.

METHOD:

The approaches reviewed include forms of minimally invasive magnetic and electrical stimulation, seizure induction, implanted devices and several highly novel approaches in early development.

RESULTS:

An extensive range of brain stimulation approaches are now being widely used in the treatment of patients with psychiatric disorders, or actively investigated for this use. Both vagal nerve stimulation (VNS) and repetitive transcranial magnetic stimulation (rTMS) have been introduced into clinical practice in some countries. A small body of research suggests that VNS has some potentially long-lasting antidepressant effects in a minority of patients treated. rTMS has now been extensively investigated for over 15 years, with a large body of research now supporting its antidepressant effects. Further rTMS research needs to focus on defining the most appropriate stimulation methods and exploring its longer term use in maintenance protocols. Very early data suggest that magnetic seizure therapy (MST) has promise in the treatment of patients referred for electroconvulsive therapy: MST appears to have fewer side effects and may have similar efficacy. A number of other approaches including surgical and alternative forms of electrical stimulation appear to alter brain activity in a promising manner, but are in need of evaluation in more substantive patient samples.

CONCLUSIONS:

It appears likely that the range of psychiatric treatments available for patients will grow over the coming years to progressively include a number of novel brain stimulation techniques.
PMID:
22044172
[PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/pubmed/22044172

Thursday, November 3, 2011

The emerging use of brain stimulation treatments for psychiatric disorders.

Aust N Z J Psychiatry. 2011 Nov;45(11):923-938.

The emerging use of brain stimulation treatments for psychiatric disorders.

Source

Monash Alfred Psychiatry Research Centre, The Alfred and Monash University School of Psychology and Psychiatry , The Alfred, First Floor Old Baker Building, Commercial Road, Melbourne, Victoria, 3004 , Australia.

Abstract

Objective: The aim of this study was to review the current state of development and application of a wide range of brain stimulation approaches in the treatment of psychiatric disorders. Method: The approaches reviewed include forms of minimally invasive magnetic and electrical stimulation, seizure induction, implanted devices and several highly novel approaches in early development. Results: An extensive range of brain stimulation approaches are now being widely used in the treatment of patients with psychiatric disorders, or actively investigated for this use. Both vagal nerve stimulation (VNS) and repetitive transcranial magnetic stimulation (rTMS) have been introduced into clinical practice in some countries. A small body of research suggests that VNS has some potentially long-lasting antidepressant effects in a minority of patients treated. rTMS has now been extensively investigated for over 15 years, with a large body of research now supporting its antidepressant effects. Further rTMS research needs to focus on defining the most appropriate stimulation methods and exploring its longer term use in maintenance protocols. Very early data suggest that magnetic seizure therapy (MST) has promise in the treatment of patients referred for electroconvulsive therapy: MST appears to have fewer side effects and may have similar efficacy. A number of other approaches including surgical and alternative forms of electrical stimulation appear to alter brain activity in a promising manner, but are in need of evaluation in more substantive patient samples. Conclusions: It appears likely that the range of psychiatric treatments available for patients will grow over the coming years to progressively include a number of novel brain stimulation techniques.

PMID:
22044172
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22044172

Friday, February 4, 2011

Magnetic device making waves in depression therapy













Tuesday, October 26, 2010

Therapeutic neuromodulation in primary headaches

Nervenarzt. 2010 Oct 24. [Epub ahead of print]

[Therapeutic neuromodulation in primary headaches.]

[Article in German]
Institut für Systemische Neurowissenschaften und Kopfschmerzambulanz der Neurologischen Klinik, Universitätsklinikum Hamburg-Eppendorf (UKE), Martinistraße 52, 20246, Hamburg, Deutschland, a.may@uke.uni-hamburg.de.

Abstract

Neuromodulatory techniques have developed rapidly in the therapeutic management of refractory headaches. Invasive procedures comprise peripheral nerve stimulation (particularly occipital nerve stimulation), vagus nerve stimulation, cervical spinal cord stimulation and hypothalamic deep brain stimulation. Transcutaneous electrical nerve stimulation, repetitive transcranial magnetic stimulation and transcranial direct current stimulation are noninvasive variants. Based on current neuroimaging, neurophysiological and clinical studies occipital nerve stimulation and hypothalamic deep brain stimulation are recommended for patients with chronic cluster headache. Less convincing evidence can be found for their use in other refractory headaches such as chronic migraine. No clear recommendation can be given for the other neuromodulatory techniques. The emerging concept of intermittent stimulation of the sphenopalatine ganglion is nonetheless promising. Robust randomized and sham-controlled multicenter studies are needed before these therapeutic approaches are widely implemented. Due to the experimental nature all patients should be treated in clinical studies.It is essential to confirm the correct headache diagnosis and the refractory nature before an invasive approach is considered. Patients should generally be referred to specialized interdisciplinary outpatient departments which closely collaborate with neurosurgeons who are experienced in the implantation of neuromodulatory devices. It is crucial to ensure a competent postoperative follow-up with optimization of stimulation parameters and adjustment of medication.
PMID: 20972665 [PubMed - as supplied by publisher